Ionis Pharmaceuticals (IONS) announced that the U.S. FDA has granted Fast Track designation to Ionis and AstraZeneca’s (AZN) eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy in adults.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
- Pharvaris price target raised to $13 from $11 at BofA
- Ionis Pharmaceuticals Reports Positive Phase 3 HAE Study Results
- Ionis Pharmaceuticals’ donidalorsen meets primary endpoint in Phase 3 HAE trial
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
